293 related articles for article (PubMed ID: 17456190)
1. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
Gouw SC; van den Berg HM; le Cessie S; van der Bom JG
J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
[TBL] [Abstract][Full Text] [Related]
2. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
[TBL] [Abstract][Full Text] [Related]
3. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.
Lusher JM; Arkin S; Abildgaard CF; Schwartz RS
N Engl J Med; 1993 Feb; 328(7):453-9. PubMed ID: 8421474
[TBL] [Abstract][Full Text] [Related]
4. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
Mariani G; Kroner B;
Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
[TBL] [Abstract][Full Text] [Related]
5. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group.
Goodeve AC; Williams I; Bray GL; Peake IR
Thromb Haemost; 2000 Jun; 83(6):844-8. PubMed ID: 10896236
[TBL] [Abstract][Full Text] [Related]
6. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group.
Bray GL; Gomperts ED; Courter S; Gruppo R; Gordon EM; Manco-Johnson M; Shapiro A; Scheibel E; White G; Lee M
Blood; 1994 May; 83(9):2428-35. PubMed ID: 8167332
[TBL] [Abstract][Full Text] [Related]
7. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
Lusher JM
Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
[TBL] [Abstract][Full Text] [Related]
8. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
[TBL] [Abstract][Full Text] [Related]
9. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate.
Guérois C; Laurian Y; Rothschild C; Parquet-Gernez A; Duclos AM; Négrier C; Vicariot M; Fimbel B; Fressinaud E; Fiks-Sigaud M
Thromb Haemost; 1995 Feb; 73(2):215-8. PubMed ID: 7792732
[TBL] [Abstract][Full Text] [Related]
10. Effects of factor VIII concentrates on the immune system of patients with hemophilia.
Mannucci PM
Thromb Haemost; 1995 Jul; 74(1):437-9. PubMed ID: 8578501
[TBL] [Abstract][Full Text] [Related]
11. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
12. Incidence of inhibitors in haemophiliacs. A review of the literature.
Scharrer I; Neutzling O
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):753-8. PubMed ID: 8292725
[TBL] [Abstract][Full Text] [Related]
13. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study.
Gouw SC; van der Bom JG; Marijke van den Berg H
Blood; 2007 Jun; 109(11):4648-54. PubMed ID: 17289808
[TBL] [Abstract][Full Text] [Related]
16. Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product.
Yee TT; Williams MD; Hill FG; Lee CA; Pasi KJ
Thromb Haemost; 1997 Sep; 78(3):1027-9. PubMed ID: 9308748
[TBL] [Abstract][Full Text] [Related]
17. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
Scandella D; Reyes H; Felch M; Sakurai Y
Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of inhibitors in haemophilia A.
Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Güngör T; Kornhuber B
Vox Sang; 1996; 70 Suppl 1():2-8. PubMed ID: 8869461
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate.
Peerlinck K; Arnout J; Di Giambattista M; Gilles JG; Laub R; Jacquemin M; Saint-Remy JM; Vermylen J
Thromb Haemost; 1997 Jan; 77(1):80-6. PubMed ID: 9031454
[TBL] [Abstract][Full Text] [Related]
20. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors.
Singer ST; Addiego JE; Reason DC; Lucas AH
Thromb Haemost; 1996 Jul; 76(1):17-22. PubMed ID: 8819245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
